$ANNX News

HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15

Annexon: Preserving Patient Function Is The Real Investment Opportunity

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Virtual Business Update Call Transcript

Annexon to Participate in Upcoming September Investor Conferences

JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14

What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX), What Is Behind Its Latest Update?

Citizens Upgrades Annexon to Market Perform

Annexon, Inc. Q2 2026 Earnings Call Summary

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

Annexon Q2 Earnings Call Highlights

Annexon shares fall as second-quarter loss exceeds Wall Street forecasts

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate